Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...

TEL AVIV, Israel (AP) — Israeli Prime Minister Benjamin Netanyahu said Sunday that Israel and Hamas are “very shortly expected to move into the second phase of the ceasefire,” after Hamas returns the ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Streaming News Wait, Did Netflix's One Piece Just Reveal We're Meeting One Of The Straw Hat Pirates Way Earlier Than Expected? Live Action Shows One Piece season 2 star David Dastmalchian says the ...

Makuochi Echebiri is a News Writer for Collider. He has been interested in creative writing from as far back as high school, and he would consume pretty much anything that’s film or TV. However, his ...

Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now it can celebrate a key trial win for its first drug to gain an FDA approval in ...

We're slowly making our way through the lunar cycle, and we're just a few days away from the full moon. The lunar cycle is a 29.5-day cycle of eight distinct phases of the moon. According to NASA, ...

The long-awaited Big Little Lies season three appears to be moving forward, perhaps at the expense of another prestige television drama. Francesca Sloane will write and executive produce the third ...

GOSS’s Seralutinib remains its main value driver. This is an inhaled TKI for PAH and PH-ILD. Seralutinib’s PROSERA Phase 3 trial is now fully enrolled with 6MWD as its primary endpoint. We should get ...